Bayer's Billion-Dollar Settlement Hangs in the Balance as Supreme Court Win Fuels a 22% Rally
Veröffentlicht: 29.06.2026 um 12:12 Uhr, Redaktion boerse-global.de
A Missouri courtroom on July 9 will determine whether Bayer can cement a $7.25 billion settlement that would resolve tens of thousands of glyphosate claims — the next critical test for a stock that has already surged more than 80% this year. The hearing comes just two weeks after the U.S. Supreme Court delivered a landmark victory for the Leverkusen-based group, ruling 7-2 on June 25 that consumers cannot sue Bayer for failing to provide cancer warnings that federal authorities did not require.
The ruling stripped thousands of pending lawsuits of their legal foundation, giving management breathing room after years of litigation drag. But the deal under review in St. Louis is designed to settle both current and future claims, and its approval would mark a definitive step toward closing the chapter on glyphosate-related risk. If the judge rejects the settlement, investors who have ridden a blistering rally may rush to take profits.
The stock closed at €46.61 on Friday, up 22.6% in the past seven days alone and within striking distance of its 52-week high. On a 12-month basis, the shares have gained roughly 82%. Yet the technical picture is flashing warning signals: the relative strength index stands at 80.6, deep in overbought territory, and annualized volatility near 58% leaves the stock vulnerable to sharp corrections.
Should investors sell immediately? Or is it worth buying Bayer?
Beyond the legal calendar, the company is pushing ahead with operational shifts and pipeline development. Since late June, Bayer has been collaborating with Iambic Therapeutics, using artificial intelligence to accelerate drug discovery — a process that traditionally takes more than a decade and costs billions. Meanwhile, its own pipeline delivered positive Phase III data for stroke-prevention drug Asundexian, which significantly reduced stroke risk versus placebo. Nubeqa and Kerendia are also gaining traction in the pharmaceuticals unit.
Management has outlined plans for a new organizational model expected to save €2 billion annually from 2026 onward, with the Crop Science division already showing margin improvement. The pharma division targets mid-single-digit growth from 2027, supported by oncology and cardiology products, and aims for an operating margin near 30% by 2030. CEO Bill Anderson has kept the door open to structural changes, including potential divestitures, though no formal breakup is on the table.
The balance sheet, however, remains strained. Net financial debt stands at roughly €33 billion, and the company expects free cash flow to be deeply negative this year — as much as minus €2.5 billion — due to around €5 billion in settlement and legal costs. Any delay in the Missouri hearing would slow deleveraging and keep pressure on the group.
For now, all eyes are on July 9. Approval would clear the path for further upside as management refocuses on growth and debt reduction. A setback, and the rally's foundation could crack quickly.
Ad
Bayer Stock: New Analysis - 29 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
